Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
We couldn't find any ticker for IMTX. Please check if the ticker was entered correctly—or if it is listed. If not, we don't have any data for that asset at the moment :(
...and much more!